news

News

Neurotoxin Jeuveau Approved by FDA as a New Facial Injectable

Americans looking to stave off and smooth any facial fine lines just got another injectable option, courtesy of the Food and Drug Administration. Jeuveau, a neurotoxin that's structurally similar to Botox, was just approved for the treatment of moderate to severe glabellar lines, which is the fancy way of saying "frown lines."

Why is this so newsworthy? Well, if you've ever consulted a dermatologist in the U.S. about fine-line-smoothing injectables, you were probably presented with one or two options — three at most — because until now, that was the number of FDA-approved neurotoxins on the market.

"This is the first new brand of neurotoxin to come to the U.S. market in almost 10 years," says Joshua Zeichner, a board-certified dermatologist based in New York City. "Any new approval is exciting, [and] new options for our aesthetic patients are always a welcomed addition to our therapeutic tool belt."

What's more, the number of aesthetic patients seems to be increasing, especially among those in the under-30 age bracket. According to the American Society of Plastic Surgeons (ASPS), neurotoxin injectable procedures have increased almost 30 percent (28 to be exact) since 2010 among 20- to 29-year-olds.

Board-certified dermatologist Sejal Shah has noticed this uptick in her New York City practice firsthand. With the news of a new neurotoxin on the market, she says if it's comparable to the options already available, she will likely offer Jeuveau in addition to her office's injectables list.

Quick refresher on how these types of injectables work: Injectable neurotoxins such as Jeuveau smooth wrinkles by temporarily paralyzing the underlying facial muscles, which sounds scarier than it actually is. The technical name for these formulas (which you may recognize from their many TV commercials) is botulinum toxin type A. Jeuveau is manufactured by California-based company Evolus, and for the time being, it is only approved to treat the appearance of frown lines in adults.

"Now, the doctors need to start trying it out in our patients to evaluate any subtle differences between Jeuveau and the other available products like Botox, Dysport, and Xeomin," Zeichner says. "Only time will tell whether it will replace the products I am currently using, but it is definitely an exciting time."

Jeuveau is set to roll out this spring at dermatologists' offices nationwide.


© 2019 WOSIAM, World Society of Interdisciplinary Aesthetic & Anti-Aging Medicine. All Rights Reserved.